165 related articles for article (PubMed ID: 32002305)
21. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
[TBL] [Abstract][Full Text] [Related]
22. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
23. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
Tan AC; Bagley SJ; Wen PY; Lim M; Platten M; Colman H; Ashley DM; Wick W; Chang SM; Galanis E; Mansouri A; Khagi S; Mehta MP; Heimberger AB; Puduvalli VK; Reardon DA; Sahebjam S; Simes J; Antonia SJ; Berry D; Khasraw M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215688
[TBL] [Abstract][Full Text] [Related]
24. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.
Santoni M; Rizzo A; Kucharz J; Mollica V; Rosellini M; Marchetti A; Tassinari E; Monteiro FSM; Soares A; Molina-Cerrillo J; Grande E; Battelli N; Massari F
Cancer Immunol Immunother; 2023 Jun; 72(6):1365-1379. PubMed ID: 36633661
[TBL] [Abstract][Full Text] [Related]
25. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
26. Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.
Chacón MR; Enrico DH; Burton J; Waisberg FD; Videla VM
JAMA Netw Open; 2018 Dec; 1(8):e185617. PubMed ID: 30646278
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.
Barnes TA; Amir E; Templeton AJ; Gomez-Garcia S; Navarro B; Seruga B; Ocana A
Cancer Treat Rev; 2017 May; 56():1-7. PubMed ID: 28437678
[TBL] [Abstract][Full Text] [Related]
28. A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.
Xu L; Wu X; Hu C; Zhang Z; Zhang L; Liang S; Xu Y; Zhang F
Onco Targets Ther; 2016; 9():4061-74. PubMed ID: 27445497
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
30. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
[TBL] [Abstract][Full Text] [Related]
31. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
33. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Xu R; Shao H; Zhu J; Ju Q; Shi H
Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study.
Yao J; Wang Z; Sheng J; Wang H; You L; Zhu X; Pan H; Han W
Int Immunopharmacol; 2020 Dec; 89(Pt A):107033. PubMed ID: 33039958
[TBL] [Abstract][Full Text] [Related]
36. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival.
Lilenbaum RC; Langenberg P; Dickersin K
Cancer; 1998 Jan; 82(1):116-26. PubMed ID: 9428487
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.
Lombardi G; Pambuku A; Bellu L; Farina M; Della Puppa A; Denaro L; Zagonel V
Crit Rev Oncol Hematol; 2017 Mar; 111():94-102. PubMed ID: 28259301
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
[TBL] [Abstract][Full Text] [Related]
39. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
Abdelhafeez AAM; Shohdy KS; Ibrahim W
Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
Alsaloumi L; Shawagfeh S; Abdi A; Basgut B
Oncol Res Treat; 2020; 43(12):694-702. PubMed ID: 32950984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
